STAT News

STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more

Novo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharma

By STAT News

1 min read
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights